Presence of immunoreactive endothelin in human plasma  by Ando, K. et al.
Volume 245, number 1,2, 164-166 FEB 06908 March 1989 
Presence of immunoreactive ndothelin in human plasma 
K. Ando*+, Y. Hirata*, M. Shichiri*, T. Emori* and F. Marumo* 
*Second Department of Internal Medicine, Tokyo Medical and Dental University, Yushima, Tokyo 113 
Volume 245, number 1,2 FEBS LETTERS March 1989 
samples was extrapolated from the standard curve linearized by 
a logit-log transformation. 
2.3. Plasma extraction 
lO-ml blood samples from normal volunteers were withdrawn 
into ice-chilled tubes containing KzEDTA, and plasma was im- 
mediately separated by centrifugation at 4°C. A 2-ml aliquot of 
plasma acidified with trifluoroacetic acid (TFA) was applied to 
Spe-Cs cartridge (J.T. Baker Chemical Co., Phillipsburg, NJ) 
prewashed sequentially with methanol, distilled water and 
0.09% TFA. The materials adsorbed to the cartridge were 
eluted with 2 ml 60% acetonitrile/0.09% TFA and evaporated 
by a centrifugal concentrator. The dried residues were 
reconstituted in the assay buffer and subjected to RIA. For 
chromatographic analysis of plasma IR-hET, 100 ml aliquot of 
pooled normal human plasma was similarly separated and sub- 
jected to reverse-phase HPLC. 
2.4. Reverse-phase HPLC 
Reverse-phase HPLC was performed using an octadecyl- 
silica column (0.45 x 25 cm, JASCO, Tokyo, Japan) eluted 
with a linear gradient of acetonitrile from 15 to 60% in 0.09% 
TFA for 1 h with a flow rate of 1 ml/mitt; l-ml fractions were 
collected and assayed for IR-hET. The recovery of standard 
hET was 96% during HPLC analysis. 
3. RESULTS 
As shown in fig.1, the minimum detectable 
quantity of hET was 0.2 fmolkube (99Vo con- 
fidence), and the 50% intercept was 6 fmolkube. 
The intra- and interassay coefficients of variation 
(n = 5) were 10 and 13%, respectively. The an- 
tibody crossreacted equally with PET and rET, 
27% with hET(16-21), and less than 0.1% with 
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Fig.1. Radioimmunoassay (RIA) for hET. Standard curve for 
hET (bars: mean + SD, n = 3) and dilution curves of normal 
human plasma extracts (o,o) are shown. Serial dilutions of 
original plasma volume are denoted above the curves. 
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Fig.2. Crossreactivities of various ET analogs in hET RIA. 
Serial dilution curves of hET(l-21) (O), rET(l-21) (A), 
hET(16-21) (o), hET(l-20) (m), hET(l-19) (m), and 
hET(l-15) (w) are shown. Total binding was 31% of ‘*‘I-hET 
added; nonspecific binding was 2.9 f 0.6% of total binding 
(n = 10). Each point is the mean of two experiments. 
hET(l-20), hET(l-19) and hET(l-15) on a molar 
basis (fig.2), whereas it did not show any 
crossreactivities with a-human atrial natriuretic 
peptide, porcine brain natriuretic peptide, 
angiotensin II or arginine-vasopressin. The dilu- 
tion curves generated from human plasma extracts 
were parallel to that of standard hET (fig.1). The 
recovery of unlabeled hET added to human plasma 
was 61 + 3% throughout the extraction procedure. 
The mean concentrations of IR-hET in 16 normal 
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Fig.3. Reverse-phase HPLC profile of IR-hET in human 
plasma extracts. Closed columns indicate the concentrations of 
IR-hET in each fraction. The elution position of standard 
hET(l-21) is shown by the arrow. A linear gradient of 
acetonitrile from 15 to 6Oqo is denoted by the solid line. 
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subjects (8 males and 8 females, aged 28.9 f 5.4 yr 
old) were 0.6 f 0.2 fmol/ml (mean -t SD). 
An elution profile of pooled human plasma ex- 
tracts on reverse-phase HPLC is shown in fig.3. 
Two major components with IR-hET were ob- 
served: one component eluted in the position of 
standard hET(l-21); while the other component, 
representing about two-thirds of the total IR-hET, 
eluted earlier than hET standard. 
4. DISCUSSION 
In the present study, we have developed a sen- 
sitive RIA for hET with a minimum detectable 
dose of 0.2 fmol, thus enabling us to measure IR- 
hET in normal human plasma. The antibody used 
in the present RIA recognizes the common 
carboxyl-terminal residues shared by hET and 
rET. Using a variety of synthetic hET analogs, the 
principal antigenic determinant of the antibody 
was shown to be C-terminal Trp” residue. This 
single amino acid residue has recently been shown 
to be essential for its biological activity [4] as well 
as receptor-binding activity (unpublished). 
Therefore, IR-hET as determined by the present 
RIA should reflect bioactive hET and related pep- 
tides. By extracting plasma with octyl-silica, the 
present study has demonstrated for the first time 
the presence of IR-hET in normal human plasma, 
of which concentrations were very low 
(0.6 fmol/ml). 
Reverse-phase HPLC revealed that IR-hET in 
human plasma consisted of at least two major 
forms. The second IR-hET component appears to 
have a retention time identical with that of authen- 
tic hET(l-21). On the other hand, the first compo- 
nent representing about two-thirds of the total 
IR-hET eluted earlier than hET( l-21), suggesting 
its weaker hydrophobicity than hET(l-21). It has 
been suggested that hET(l-21) is generated from 
‘big-ET’, an intermediate form with 39-amino acid 
residues, through an unusual proteolytic process- 
ing [I]. Big-ET has a C-terminal extension with 
more hydrophilic residues. Therefore, it is possible 
that the major IR-hET component in human 
plasma may be a big-hET and/or related peptides. 
The precise mechanism of posttranslational pro- 
cessing of hET in vivo remains to be determined. 
In conclusion, our study demonstrates the 
presence of IR-hET in human plasma, suggesting 
that it has a potential role as a circulating hor- 
mone. Determination of plasma levels of IR-hET 
in normal and pathological conditions should pro- 
vide important clues to understanding its 
physiological and pathophysiological role(s) in 
man. 
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